Omalizumab for asthma
RC Strunk, GR Bloomberg - New England Journal of Medicine, 2006 - Mass Medical Soc
RC Strunk, GR Bloomberg
New England Journal of Medicine, 2006•Mass Medical SocA 16-year-old boy with a history of severe persistent asthma despite treatment with inhaled
corticosteroids presents for evaluation. Treatment with omalizumab, a monoclonal anti-IgE
antibody, is recommended. This agent has been found to reduce the frequency of
exacerbations of asthma in clinical trials. It is not known how the efficacy of omalizumab
compares with that of other available therapies. The drug is more expensive than other
agents.
corticosteroids presents for evaluation. Treatment with omalizumab, a monoclonal anti-IgE
antibody, is recommended. This agent has been found to reduce the frequency of
exacerbations of asthma in clinical trials. It is not known how the efficacy of omalizumab
compares with that of other available therapies. The drug is more expensive than other
agents.
A 16-year-old boy with a history of severe persistent asthma despite treatment with inhaled corticosteroids presents for evaluation. Treatment with omalizumab, a monoclonal anti-IgE antibody, is recommended. This agent has been found to reduce the frequency of exacerbations of asthma in clinical trials. It is not known how the efficacy of omalizumab compares with that of other available therapies. The drug is more expensive than other agents.
The New England Journal Of Medicine